Physicians' Academy for Cardiovascular Education

Lessons from the biology of CETP inhibition

10' education - Aug. 2, 2022 - Prof. John Kastelein, MD, PhD

Key innovations in lipid treatment

5' education - Aug. 2, 2022 - Prof. Chris Packard, PhD

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022

Expanding evidence on SGLT2i: Where are we now and what can we expect?

10' education - July 21, 2022 - Prof. Scott Solomon, MD

Triglycerides most commonly a marker of ectopic fat accumulation

5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD

Discussion - Clinical dilemmas in heart failure: Weighing the balance of RAASi and hyperkalaemia

10' education - July 20, 2022 - Prof. Andrew Coats, MD, Clara Bonanad Lozano, MD, PhD, and Aaron Wong, MD

Potassium binders as enablers of RAASi therapy

10' education - July 19, 2022 - Prof. Javed Butler, MD and prof. Stefan Anker, MD, PhD

Potassium binding as RAASi enabling therapy: applying recent insights into practice

10' education - July 18, 2022 - Aaron Wong, MD

Optimizing treatment for patients with HoFH

10' education - July 13, 2022 - Prof. Erik Stroes, MD, PhD

Primary care as gatekeeper in CKD and the need for collaboration with nephrologists

10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD

New perspectives on the management of HFrEF: iron deficiency and cardiac remodeling

10' education - July 12, 2022 - Prof. Peter van der Meer, MD, PhD and Pieter Martens, MD, PhD

Hyperkalemia in heart failure: Why should we care?

10' education - July 12, 2022 - Clara Bonanad Lozano, MD, PhD

Discussion - Rethinking the role of nephrologists in prevention of CKD - The opportunity of early risk identification

10' education - July 6, 2022 - Prof. Christoph Wanner, MD, Rikke Borg, MD, PhD, and prof. Kamlesh Khunti, MD, PhD

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD

Why is early screening and risk identification of CKD in diabetes important?

10' education - July 6, 2022 - Rikke Borg, MD, PhD

Optimizing RAASi therapy: The role of personalized therapy

10' education - July 5, 2022 - Prof. George Bakris, MD and prof. Giuseppe Rosano, MD, PhD

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity

15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD

HoFH: Why is early diagnosis important?

10' education - June 29, 2022 - Prof. Kausik Ray, MD

Lessons from the biology of CETP inhibition

10' education - Aug. 2, 2022 - Prof. John Kastelein, MD, PhD

"It has become apparent that the reduction in atherogenic lipoproteins drives CHD protection by CETP inhibition - not changes in HDL-c", says Prof. Kastelein. He explains this statement by findings from studies.

Key innovations in lipid treatment

Lipid lessons

5' education - Aug. 2, 2022 - Prof. Chris Packard, PhD
Prof. Packard gives a short overview of where we stand with regard to innovations for lipid lowering - in the secondary, primary, and primordial setting.

Prof. Packard gives a short overview of where we stand with regard to innovations for lipid lowering - in the secondary, primary, and primordial setting.

Several biomarkers identified as predictors of outcomes in hypertrophic cardiomyopathy

Literature - Aug. 1, 2022 - Jansen M, et al. - ESC Heart Fail. 2022 Jul 17. doi: 10.1002/ehf2.14073

A systematic review and meta-analysis identified several biomarkers that predicted outcomes in hypertrophic cardiomyopathy, which have the potential to improve risk stratification in this patient group.

Women, not men, with high sodium intake may benefit from high potassium diet

Literature - Aug. 1, 2022 - Wouda RD, et al. - Eur Heart J. 2022

Analysis of a population-based cohort showed sex-specific differences in the association of daily potassium intake with both SBP and CV events. In women, sodium intake modified the association with SBP.

Moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in ASCVD

Literature - Aug. 1, 2022 - Kim BK, et al. - Lancet. 2022

A randomized study compared the 3-year efficacy and safety of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with ASCVD.

Network meta-analysis of LLTs in patients with hypercholesterolemia and high CV risk

Literature - July 28, 2022 - Burnett H, et al. - Curr Med Res Opin. 2022

There have been no direct comparative studies of inclisiran, evolocumab, alirocumab, bempedoic acid, and ezetimibe in patients with hypercholesterolemia and increased cardiovascular risk receiving maximal tolerated statin therapy. A network meta-analysis may provide further insight.

DOAC antidote vs. prothrombin complex in DOAC-related intracranial hemorrhage

Literature - July 25, 2022 - Costa OS, et al. - Crit Care. 2022

This study indirectly compared the effectiveness of andexanet alfa versus four‑factor prothrombin complex concentrate in adults in whom anticoagulation reversal is needed because of apixaban- or rivaroxaban-related life-threatening or uncontrolled bleeding.

SGLT2i attenuates longitudinal rises in CV biomarkers in T2DM patients

Literature - July 25, 2022 - Vaduganathan M, et al. - J Am Coll Cardiol. 2022

The CANVAS biomarker substudy showed that canagliflozin delays the expected increase in CV biomarkers in T2DM patients. It also reduces the risk of HF and renal disease events irrespective of biomarker levels at baseline.

Intolerance to ARNI is common in advanced chronic HFrEF

Literature - July 25, 2022 - Vader JM, et al . - JACC Heart Fail. 2022

During a short run-in period of the LIFE trial, 18% of patients with advanced chronic HFrEF were intolerant of low-dose sacubitril/valsartan. Intolerance was predicted by several risk factors, such as low serum chloride.

Concomitant use of ARNI does not alter the efficacy of sGC stimulator in HFrEF

Literature - July 25, 2022 - Senni M, et al. - Eur J Heart Fail. 2022

The VICTORIA trial showed beneficial effects of vericiguat in patients with HFrEF. However, it is unclear whether this drug is also effective and safe in patients with HFrEF who are treated concomitantly with sacubitril/valsartan.

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD
Prof. Raal presents a case of a 16-year old female with homozygous familial hypercholesterolemia (HoFH) and discusses the cumulative LDL-c lowering effects of different  therapies in this patient.

Prof. Raal presents a case of a 16-year old female with homozygous familial hypercholesterolemia (HoFH) and discusses the cumulative LDL-c lowering effects of different therapies in this patient.

Expanding evidence on SGLT2i: Where are we now and what can we expect?

10' education - July 21, 2022 - Prof. Scott Solomon, MD
Prof. Solomon talks about unanswered questions with SGLT2 inhibitors and discusses the study design of the DELIVER, a phase 3 trial with dapagliflozin in patients with HF and LVEF>40%.

Prof. Solomon talks about unanswered questions with SGLT2 inhibitors and discusses the study design of the DELIVER, a phase 3 trial with dapagliflozin in patients with HF and LVEF>40%.